Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 15 vs ADDERALL 7.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
The terminal elimination half-life of amphetamine is approximately 10-13 hours in adults, but can vary based on urinary p H (alkaline urine prolongs half-life up to 20 hours; acidic urine reduces it to 7-8 hours). In children, half-life is slightly shorter (6-8 hours). Clinical context: Steady-state is achieved within 2-3 days.
Amphetamine is metabolized primarily by hepatic CYP2D6 and to a lesser extent by CYP2C19 and CYP2C9, with some minor pathways involving dopamine beta-hydroxylase.
Amphetamine and dextroamphetamine are metabolized primarily in the liver via oxidative deamination and aromatic hydroxylation. The major metabolic pathway involves the enzyme CYP2D6, which converts amphetamine to 4-hydroxyamphetamine and norephedrine. Other minor pathways include N-dealkylation and deamination.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites (including deaminated and hydroxylated products). Fecal excretion is negligible (<5%).
~16-20%; primarily binds to albumin, with minor binding to alpha-1-acid glycoprotein.
Approximately 20-25% bound to plasma proteins (primarily albumin).
Vd: 3.0-4.5 L/kg (range 2.6-5.6); indicates extensive tissue distribution, including brain, with accumulation in kidneys and liver.
Apparent volume of distribution is approximately 3-4 L/kg, indicating extensive tissue distribution, with high concentrations in the brain and cerebrospinal fluid.
Oral: ~76% (range 64-95%) for mixed amphetamine salts; bioavailability reduced by acidic gastric p H and increased with food (Tmax delayed but AUC unchanged).
Oral bioavailability is approximately 75-80% for immediate-release formulations, with no significant food effect. Extended-release capsules have similar bioavailability when taken intact.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: contraindicated.
e GFR 30-89 m L/min: Administer 50% of usual dose; e GFR <30 m L/min: Not recommended due to accumulation; Hemodialysis: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh Class A: No adjustment necessary; Child-Pugh Class B: Reduce dose by 50%; Child-Pugh Class C: Not recommended.
Weight-based: <50 kg: 2.5-5 mg once daily; 50-100 kg: 5-10 mg once daily; >100 kg: adult dosing.
Children ≥3 years (ADHD): Immediate-release: Starting dose 2.5 mg once or twice daily, increase by 2.5-5 mg/day weekly to max 40 mg/day in divided doses; Extended-release: ≥6 years: Starting 10 mg once daily, increase by 5-10 mg weekly to max 30 mg/day. Weight <30 kg: Use lower end of dosing range.
Start at 2.5-5 mg once daily; increase slowly due to increased sensitivity and cardiovascular risk.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg at weekly intervals; maximum 40 mg/day; monitor for cardiovascular effects, insomnia, and appetite suppression.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence throughout therapy.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including ADDERALL, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events (exacerbation of pre-existing psychosis, manic episodes, aggressive behavior),Seizures (may lower seizure threshold),Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk, especially with concomitant serotonergic drugs,Long-term growth suppression in children
Serious Cardiovascular Events: Sudden death, stroke, and myocardial infarction have been reported in patients with pre-existing structural cardiac abnormalities.,Blood Pressure and Heart Rate Increases: Monitor heart rate and blood pressure; use caution in patients with hypertension or tachycardia.,Psychiatric Adverse Events: May exacerbate pre-existing psychosis, mania, or cause new psychotic/manic symptoms.,Seizures: May lower seizure threshold; use with caution in patients with a history of seizures.,Peripheral Vasculopathy: Including Raynaud's phenomenon; monitor for digital changes.,Serotonin Syndrome: Risk when co-administered with serotonergic drugs.,Growth Suppression: Monitor growth in pediatric patients during treatment.,Abuse and Dependence: High potential; prescribe cautiously and monitor for misuse.
Hypersensitivity to amphetamine or other components,Concurrent use or within 14 days of MAOIs (risk of hypertensive crisis),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (symptomatic, moderate to severe hypertension, advanced arteriosclerosis, structural cardiac abnormalities)
Hypersensitivity to amphetamines or any components of the formulation,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Symptomatic cardiovascular disease,Moderate to severe hypertension,Advanced arteriosclerosis
Avoid high-fat meals close to dosing as they may delay absorption. Acidic foods (e.g., citrus, cola, vitamin C) can decrease absorption; take with non-acidic fluids. Avoid alcohol and caffeine-containing products.
Take with or without food, but consistency is recommended to avoid fluctuating absorption. Avoid acidic foods or large amounts of vitamin C (e.g., citrus fruits, juices) within 1 hour of dosing, as they can decrease absorption. Avoid high-fat meals which can delay absorption. Grapefruit and grapefruit juice may increase amphetamine levels; limit or avoid.
First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/third trimesters: Risk of fetal growth restriction, preterm delivery, neonatal withdrawal (irritability, feeding problems), and persistent pulmonary hypertension.
Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (e.g., cardiac, oral clefts) based on amphetamine class; insufficient human data. Second/third trimester: Risk of preterm delivery, low birth weight, and neonatal withdrawal (e.g., irritability, poor feeding).
Present in breast milk; M/P ratio approximately 2.5-7.5. Potential for infant stimulation, insomnia, reduced weight gain. Caution recommended; consider delaying breastfeeding until 1-2 hours after dose.
Amphetamines are excreted into breast milk. M/P ratio unknown. Potential for infant stimulation, insomnia, and growth suppression. Breastfeeding not recommended during therapy.
Pregnancy reduces amphetamine plasma concentrations by 15-50% during second/third trimesters due to increased clearance. Dose may need upward titration to maintain clinical effect, with careful monitoring for adverse effects.
Decreased plasma levels due to increased volume of distribution and hepatic metabolism; dose may need to be increased, but risk-benefit must be evaluated. Use lowest effective dose with close monitoring.
Adderall 15 mg (amphetamine/dextroamphetamine) is an immediate-release formulation; onset 30-60 min, duration 4-6 hours. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Consider drug holidays to assess need and reduce tolerance. Do not use with MAOIs or within 14 days of MAOI therapy. Risk of abuse and dependence; screen for substance use history. Use with caution in patients with pre-existing cardiovascular disease or psychiatric disorders.
Adderall 7.5 mg is a combination of amphetamine salts (dextroamphetamine and levoamphetamine) in a 3:1 ratio. It is a CNS stimulant indicated for ADHD and narcolepsy. Monitor for cardiovascular effects (BP, HR) prior to and during therapy. Use with caution in patients with hypertension, tachyarrhythmias, or history of substance abuse. Avoid concomitant use with MAOIs or within 14 days of discontinuation. May cause growth suppression in children; monitor height and weight. Abuse potential is high; prescribe the smallest effective dose and use tamper-resistant formulations when possible.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose in the morning; if prescribed a second dose, take it by early afternoon to avoid sleep problems.,Swallow tablet whole; do not crush or chew.,Avoid alcohol and caffeine; may increase side effects like nervousness and rapid heartbeat.,Report chest pain, palpitations, shortness of breath, or fainting immediately.,Inform your doctor of all medications, including over-the-counter and herbal products, especially antidepressants.,May cause weight loss; monitor growth in children.,Can impair ability to drive or operate machinery until you know how it affects you.,Store at room temperature away from moisture and heat.,Do not abruptly stop; taper under medical supervision to avoid withdrawal.
Take exactly as prescribed; do not take more or more often than directed.,Swallow tablets whole; do not crush, chew, or break them.,Avoid taking late in the day to prevent insomnia.,Do not stop abruptly; sudden discontinuation can cause severe fatigue and depression.,Notify your doctor of any history of heart problems, high blood pressure, seizures, or mental health conditions.,Report any chest pain, shortness of breath, fainting, or seizures immediately.,Avoid alcohol and marijuana; they can increase side effects.,Store at room temperature away from moisture and heat.,Keep out of reach of children; this medication has a high risk of overdose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 15 vs ADDERALL 7.5, answered by our medical review team.
ADDERALL 15 is a CNS Stimulant that works by Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.. ADDERALL 7.5 is a CNS Stimulant that works by ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 15 and ADDERALL 7.5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 15 is: 10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.. The standard adult dose of ADDERALL 7.5 is: 5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 15 and ADDERALL 7.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 15 is classified as Category C. First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/t. ADDERALL 7.5 is classified as Category C. Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (e.g., cardiac, oral clefts) based on amphetamine class; insufficient human data. Second/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.